Synthesis and evaluation of double-prodrugs against HIV. Conjugation of D4T with 6-benzyl-1-(ethoxymethyl)-5-isopropyluracil (MKC-442, emivirine)-type reverse transcriptase inhibitors via the SATE prodrug approach

Journal of Medicinal Chemistry

Volumn 48, Issue 4, 2005, Pages 1211-1220

  Petersen, Lene ^a   Jørgensen, Per T ^a   Nielsen, Claus ^b   Hansen, Thomas H ^c   Nielsen, John ^a,c   Pedersen, Erik B ^a  

^a UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^b STATENS SERUM INSTITUT   (Denmark)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

2 THIOETHYL ESTER; 4 HYDROXYBENZOIC ACID; 6 (3,5 DIMETHYLBENZYL) 5 ETHYL 1 (4 HYDROXYBENZYLOXYMETHYL) 1H PYRIMIDINE 2,4 DIONE; 6 (3,5 DIMETHYLBENZYL) 5 ETHYL 1 [3 (4 HYDROXYPHENYL)ALLYLOXYMETHYL] 1H PYRIMIDINE 2,4 DIONE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; AROMATIC COMPOUND; CYSTEINE; EMIVIRINE; PHENOL; PHOSPHATE; PRODRUG; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TYROSINE; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ARTICLE; CONJUGATION; CONTROLLED STUDY; CROSS LINKING; DRUG SENSITIVITY; DRUG STABILITY; DRUG SYNTHESIS; ENZYME INHIBITION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2; NONHUMAN; STRUCTURE ACTIVITY RELATION; VIRUS MUTANT;

CELL LINE; DRUG RESISTANCE, VIRAL; HIV-1; HIV-2; HUMANS; MUTATION; PRODRUGS; REVERSE TRANSCRIPTASE INHIBITORS; STAVUDINE; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; SULFIDES; THYMIDINE MONOPHOSPHATE; URACIL;

EID: 13944259677     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm040845b     Document Type: Article

References (47)

1. Squires, K. E. An introduction to nucleoside and nucleotide analogues. Antiviral Ther. 2001, 6, 1-14.
2. (a) Buckheit, R. W. Nonnucleoside reverse transcriptase inhibitors: perspectives on novel therapeutic compounds and strategies for the treatment of HIV infection. Expert Opin. Invest. Drugs. 2001, 10, 1423-1442.
3. (b) Hogberg, M.; Morrison, I. HIV-1 nonnucleoside reverse transcriptase inhibitors. Expert Opin. Ther. Pat. 2000, 10, 1189-1199.
4. (c) Pedersen, O. S.; Pedersen, E. B. Nonnucleoside reverse transcriptase inhibitors: the NNRTI boom. Antiviral Chem. Chemother. 1999, 10, 285-314.
5. (a) Anastasi, C.; Quelever, G.; Burlet, S.; Garino, C.; Souard, F.; Kraus, J.-L. New antiviral nucleoside prodrugs await application. Curr. Med. Chem. 2003, 10, 1825-1843.
6. (b) Calogeropoulou, T.; Detsi, A.; Lekkas, E.; Koufaki, M. Strategies in the design of prodrugs of anti-HIV agents. Curr. Top. Med. Chem. 2003, 3, 1467-1495.
7. (c) Cooperwood, J. S.; Gumina, G.; Boudinot, F. D.; Chu, C. K. Nucleoside and nucleotide prodrugs. Recent Adv. Nucleosides 2002, 91-147.
8. (d) Wagner, C. R.; Iyer, V. V.; McIntee, E. J. Pronucleotides: Toward the in vivo delivery of antiviral and anticancer nucleotides. Med. Res. Rev. 2000, 20, 417-451.
9. (e) Kukhanova, M.; Krayevsky, A.; Prusoff, W.; Cheng, Y.-C. Design of anti-HIV compounds: from nucleoside to nucleoside 5′-triphosphate analogues. Problems and perspectives. Curr. Pharm. Des. 2000, 6, 585-598.
10. (f) Meier, C. Pro-nucleotides. Recent advances in the design of efficient tools for the delivery of biologically active nucleoside monophosphates. Synlett 1998, 233-242.
11. Périgaud, C.; Gosselin, G.; Lefebvre, I.; Girardet, J.-L.; Benzaria, S.; Barber, I.; Imbach, J.-L. Rational design for cytosolic delivery of nucleoside monophosphates: "SATE" and "DTE" as enzyme-labile transient phosphate protecting groups. Bioorg. Med. Chem. Lett. 1993, 3, 2521-2526.
12. Lefebvre, I.; Périgaud, C.; Pompon, A.; Aubertin, A.-M.; Girardet, J.-L.; Kirn, A.; Gosselin, G.; Imbach, J.-L. Mononucleoside Phosphotriester Derivatives with S-acyl-2-thioethyl bioreversible phosphate-protecting groups: intracellular delivery of 3′-azido-2′,3′-dideoxythymidine 5′-monophosphate. J. Med. Chem. 1995, 38, 3941-3950.
13. Girardet, J.-L.; Périgaud, C.; Aubertin, A.-M.; Gosselin, G.; Kirn, A.; Imbach, J.-L. Increase of the anti-HIV activity of d4T in human T-cell culture by the use of the SATE pronucleotide approach. Bioorg. Med. Chem. Lett. 1995, 5, 2981-2984.
14. (a) Peyrottes, S.; Egron, D.; Lefebvre, I.; Gosselin, G.; Imbach, J.-L.; Périgaud, C. SATE pronucleotide approaches: An overview. Mini-Rev. Med. Chem. 2004, 4, 395-321.
15. (b) Peyrottes, S.; Coussot, G.; Lefebvre, I.; Imbach, J.-L.; Gosselin, G.; Aubertin, A.-M.; Périgaud, C. S-Acyl-2-thioethyl aryl phosphotrieter derivatives of AZT: Stynthesis, antiviral activity, and stability study. J. Med. Chem. 2003, 46, 782-793.
16. (c) Peyrottes, S.; Schlienger, N.; Beltran, T.; Lefebvre, I.; Pompon, A.; Gosselin, G.; Aubertin, A.-M.; Imbach, J.-L.; Périgaud, C. Design of new mononucleotide prodrugs: aryl (SATE) phosphotriester derivatives. Nucleosides, Nucleotides Nucleic Acids 2001, 20, 315-321.
17. (d) Schlienger, N.; Peyrottes, S.; Kassem, T.; Imbach, J.-L.; Gosselin, G.; Aubertin, A.-M.; Périgaud, C. S-Acyl-2-thioethyl aryl phosphotriester derivatives as mononucleotide prodrugs. J. Med. Chem. 2000, 43, 4570-4574.
18. (e) Schlienger, N.; Beltran, T.; Périgaud, C.; Lefebvre, I.; Pompon, A.; Aubertin, A.-M.; Gosselin, G.; Imbach, J.-L. Rational design of a new series of mixed anti-HIV pronucleotides. Bioorg. Med. Chem. Lett. 1998, 8, 3003-3006.
19. Schlienger, N.; Peyrottes, S.; Aubertin, A.-M.; Gosselin, G.; Imbach, J.-L.; Périgaud, C. New series of mixed pronucleotides. Synthesis and anti-HIV activities of mononucleoside phenyl SATE phosphotriesters. Nucleosides Nucleotides 1999, 18, 1025-1026.
20. (a) Tanaka, H.; Takashima, H.; Ubasawa, M.; Sekiya, K.; Inouye, N.; Baba, M.; Shigeta, S.; Walker, R. T.; De Clercq, E.; Miyasaka, T. Synthesis and antiviral activity of 6-benzyl analogues of 1-[(2-hydroxyethoxy)methyl]-6- (phenylthio)thymine (HEPT) as potent and selective anti-HIV-1 agents. J. Med. Chem. 1995, 38, 2860-2865.
21. (b) Baba, M.; Shigeta, S.; Yuasa, S.; Takashima, H.; Sekiya, K.; Ubasawa, M.; Tanaka, H.; Miyasaka, T.; Walker, R. T.; De Clercq, E. Preclinical evaluation of MKC-442, a highly potent and specific inhibitor of human immunodeficiency virus type 1 in vitro. Antimicrob. Agents Chemother. 1994, 38, 688-692.
22. (c) Yuasa, S.; Sadakata, Y.; Takashima, H.; Sekiya, K.; Inouye, N.; Ubasawa, M.; Baba, M. Selective and synergistic inhibition of human immunodeficiency virus type 1 reverse transcriptase by a nonnucleoside inhibitor, MKC-442. Mol. Pharmacol. 1993, 44, 895-900.
23. (d) Szcech, G. M.; Furman, P.; Painter, G. R.; Barry, D. W.; Borroto-Esoda, K.; Grizzle, T. B.; Blum, M. R.; Sommadossi, J.-P.; Endoh, R.; Niwa, T.; Yamamoto, M.; Moxham, C. Safety assessment, in vitro and in vivo, and pharmacokinetics of Emivirine, a potent and selective nonnucleoside reverse transcriptase inhibitor of human immunodeficiency virus type 1. Antimicrob. Agents Chemother. 2000, 44, 123-130.
24. El-Brollosy, N. R.; Jørgensen, P. T.; Dahan, B.; Boel, A.-M.; Pedersen, E. B.; Nielsen, C. Synthesis of novel N-1 (allyloxymethyl) analogues of MKC-442 (Emivirine) with improved activity against HIV-1 and its mutants. J. Med. Chem. 2002, 45, 5721-5726.
25. El-Brollosy, N. R.; Pedersen, E. B.; Nielsen, C. Synthesis of novel MKC-442 analogues with potent activities against HIV-1. Arch. Pharm. Pharm. Med. Chem. 2003, 336, 236-241.
26. Balzarini, J.; Herdewijn, P.; De Clercq, E. Differential patterns of intracellular metabolism of 2′,3′-didehydro-2′,3′- dideoxythymidine and 3′-azido-2′,3′-dideoxythymidine, two potent anti-human immunodeficiency virus compounds. J. Biol. Chem. 1989, 264, 6127-6133.
27. Ho, H.-T.; Hitchcock, M. J. M. Cellular pharmacology of 2′,3′-dideoxy-2′,3′-didehydrothymidine, a nucleoside analogue active against human immunodeficiency virus. Antimicrob. Agents Chemother. 1989, 33, 844-849.
28. Bosshard, H. H.; Mory, R.; Schmid, M.; Zollinger, H. Eine methode zur katalysierten herstellung von carbonsäure- und sulfosäure-chloriden mit thionylchlorid. Helv. Chim. Acta 1959, 42, 1653-1658.
29. (a) Danel, K.; Larsen, E.; Pedersen, E. B.; Vestergaard, B. F.; Nielsen, C. Synthesis and potent anti-HIV-1 activity of novel 6-benzyluracil analogues of 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine. J. Med. Chem. 1996, 39, 2427-2431.
30. (b) Danel, K.; Larsen, E.; Pedersen, E. B. Easy synthesis of 5,6-disubstituted acyclouridine derivatives. Synthesis 1995, 8, 934-936.
31. 2O), 116.22, 119.80, 122.76, 127.23, 127.47, 129.37, 133.084, 134.90, 149.25, 150.89, 161.83, 163.21, 167.37 (C-aryl, CO).
32. Lefebvre, I.; Périgaud, C.; Pompon, A.; Aubertin, A.-M.; Girardet, J.-L.; Kirn, A.; Gosselin, G.; Imbach, J.-L. Mononucleoside phosphotriester derivatives with S-acyl-2-thioethyl bioreversible phosphate-protecting groups: intracellular delivery of 3′-azido-2′,3′-dideoxythymidine 5′-monophosphate. J. Med. Chem. 1995, 38, 3941-3950.
33. We thank Dr. D. Egron for advice on the synthesis of (S-pivaloyl-2- thioethyl)-N,N-bis(diisopropylamino)phosphine.
34. D4T was synthesized on a gram scale according to the following procedures: (a) Horwitz, J. P.; Chua, J.; Da Rooge, M. A.; Noel, M.; Klundt, I. L. Nucleosides. IX. The formation of 2′,3′-unsaturated pyrimidine nucleosides via a novel β-elimination reaction. J. Org. Chem. 1966, 31, 205-211.
35. (b) Mansuri, M. M.; Starrett, J. E.; Ghazzouli, I.; Hitchcock, M. J. M.; Sterzycki, R. Z.; Brankovan, V.; Lin, T.-S.; August, E. M.; Prusoff, W. H.; Sommadossi, J.-P.; Martin, J. C. 1-(2,3-Dideoxy-β-D-glycero-pent-2- enofuranosyl)thymine. A highly potent and selective anti-HIV agent. J. Med. Chem. 1989, 32, 461-466.
36. Cernerud, M.; Reina, J. A.; Tegenfeldt, J.; Moberg, C. Chiral polymers via asymmetric epoxidation and asymmetric dihydroxylation. Tetrahedron: Asymmetry 1996, 7, 2863-2870.
37. Quideau, S.; Ralph, J. Facile large-scale synthesis of coniferyl, sinapyl, and p-coumaryl alcohol. J. Agric. Food Chem. 1992, 40, 1108-1110.
38. Srivastava, V.; Tandon, A.; Ray, S. Convenient and selective acetylations of phenols, amines and alcohols. Synth. Commun. 1992, 22, 2703-2710.
39. Dimmock, J. R.; Puthucode, R. N.; Smith, J. M.; Hetherington, M.; Quail, J. W.; Pugazhenthi, U.; Lechler, T.; Stables, J. P. (Aryloxy)aryl semicarbazones and related compounds: a novel class of anticonvulsant agents possessing high activity in the maximal electroshock screen. J. Med. Chem. 1996, 39, 3984-3997.
40. Daubresse, N.; Francesch, C.; Mhamdi, F.; Rolando, C. A Mild synthesis of coumaryl, coniferyl, sinapyl aldehydes and alcohols. Synthesis 1994, 369-371.
41. Esteban-Gamboa, A.; Balzarini, J.; Esnouf, R.; De Clercq, E.; Camarasa, M.-J., Pérez-Pérez, M.-J. Design, synthesis, and enzymatic evaluation of multisubstrate analogue inhibitors of Escherichia coli thymidine phosphorylase. J. Med. Chem. 2000, 43, 971-983.
42. 3. A convenient, versatile preparation of chloromethyl ether derivatives. J. Org. Chem. 1986, 51, 4711-4714.
43. Vorbrüggen, H.; Krolikiewicz, K.; Bennua, B. Nucleoside synthesis with trimethylsilyl triflate and perchlorate as catalysts. Chem. Ber. 1981, 114, 1234-1255.
44. Hopkins, A. L.; Ren, J.; Esnouf, R. M.; Willcox, B. E.; Jones, E. Y.; Ross, C.; Miyasaka, T.; Walker, R. T.; Tanaka, H.; Stammers, D. K.; Stuart, D. I. Complexes of HIV-1 reverse transcriptase with inhibitors of the HEPT series reveal conformational changes relevant to the design of potent nonnucleoside inhibitors. J. Med. Chem. 1996, 39, 1589-1600.
45. Benneche, T.; Strande, P.; Undheim, K. A new synthesis of chloromethyl benzyl ethers. Synthesis 1983, 762-763.
46. Mosmann, T. Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. J. Immunol. Methods 1983, 65, 55-63.
47. Nielsen, C. M.; Bygbjerg, I. C.; Vestergaard, B. F. Detection of HIV antigens in eluates from whole blood collected on filter paper. Lancet 1987, 329, 566-567.